
-
Trump says bringing $15 bn lawsuit against New York Times
-
Israel sets Gaza 'on fire' as Rubio warns days left for deal
-
Phillies clinch first MLB division by beating Dodgers
-
'Nothing here': Lack of jobs forces young Nepalis abroad
-
Rubio asks Qatar to stay as mediator after Israeli strike
-
Trump set for unprecedented second UK state visit
-
Lower US tariffs on Japan autos kick in
-
Revamped Bayern face early test as Chelsea come to town
-
Papua New Guinea, Australia to vow mutual defence in new treaty
-
Malawi election a battle of two presidents
-
Asian markets rise as traders prepare for expected US rate cut
-
Malawi votes in a rematch between two presidents as economic crisis bites
-
Australia says social media ban will not age test all users
-
Poland's Nawrocki talks drone defence in Paris and Berlin
-
Trump's fossil fuel agenda challenged in youth climate suit
-
PSG fear impact of injuries as they put Champions League title on the line
-
US Senate confirms Trump aide to Fed as politics loom over rate meeting
-
Papua New Guinea, Australia will commit to mutual defence
-
Trash, mulch and security: All jobs for troops in Washington
-
Tocvan Announces Commencement Of Field Work And Airborne Magnetics Survey At Gran Pilar Gold Silver Project; Drilling And Trenching Prep Accelerate Discovery & Pilot Mine Production
-
NFL legend Brady to play in March flag football event at Riyadh
-
Lower US tariffs on Japan autos to take effect Tuesday
-
US strikes second alleged Venezuelan drug boat as tensions mount
-
Protesting Peru residents block trains to Machu Picchu
-
US strikes another alleged Venezuelan drug boat as tensions rise
-
White House vows to take on left-wing 'terror' movement after Kirk killing
-
Brazil's Amazon lost area the size of Spain in 40 years: study
-
US Senate poised to advance Trump aide's appointment at Fed
-
Sri Lanka survive Hong Kong scare for four wicket Asia Cup win
-
Arab, Muslim leaders urge review of Israel ties after Qatar attack
-
Mbappe 'not anxious' over Champions League goal as Bellingham returns
-
Huge pot of Nigerian jollof rice sets Guinness record
-
Heartbreak will help Arsenal's Champions League charge: Arteta
-
Europe stumped by Trump demands over Russia sanctions
-
Cycling fears spread of race-halting protests after Vuelta chaos
-
US, China reach 'framework' deal on TikTok ownership
-
'With our fists if necessary': Venezuelans prepare to defend homeland against potential US invasion
-
Duplantis thrives on Tokyo energy to break world record again
-
Ex-France defender Umtiti calls time on club career
-
One in six US parents rejecting standard vaccine schedule: poll
-
Sheffield Utd appoint Wilder for third managerial spell
-
UAE hammer Oman in Asia Cup to keep Super Four hopes alive
-
Activists on trial as France debates right to die
-
Duplantis reaches new heights, Beamish makes Kiwi history at worlds
-
Frank relishing Champions League debut with Spurs
-
Spanish PM calls for Israel to be barred from international sport
-
UK aristocrat, partner get 14 years for baby daughter's manslaughter
-
US says 'framework' deal with China on TikTok ownership
-
Shootings 'unjustified' in Bloody Sunday killings, Belfast court hears
-
Three French women accused of IS links go on trial

Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
S.F.Warren--AMWN